163 related articles for article (PubMed ID: 35278271)
1. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK.
Shi X; Yu X; Wang J; Bian S; Li Q; Fu F; Zou X; Zhang L; Bast RC; Lu Z; Guo L; Chen Y; Zhou J
Mol Oncol; 2022 Jul; 16(13):2558-2574. PubMed ID: 35278271
[TBL] [Abstract][Full Text] [Related]
2. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer.
Wang F; Yu X; Qian J; Cao Y; Dong S; Zhan S; Lu Z; Bast RC; Song Q; Chen Y; Zhang Y; Zhou J
Drug Resist Updat; 2024 May; 74():101077. PubMed ID: 38518726
[TBL] [Abstract][Full Text] [Related]
3. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.
Miranda F; Mannion D; Liu S; Zheng Y; Mangala LS; Redondo C; Herrero-Gonzalez S; Xu R; Taylor C; Chedom DF; Carrami EM; Albukhari A; Jiang D; Pradeep S; Rodriguez-Aguayo C; Lopez-Berestein G; Salah E; Abdul Azeez KR; Elkins JM; Campo L; Myers KA; Klotz D; Bivona S; Dhar S; Bast RC; Saya H; Choi HG; Gray NS; Fischer R; Kessler BM; Yau C; Sood AK; Motohara T; Knapp S; Ahmed AA
Cancer Cell; 2016 Aug; 30(2):273-289. PubMed ID: 27478041
[TBL] [Abstract][Full Text] [Related]
4. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
Gao T; Zhang X; Zhao J; Zhou F; Wang Y; Zhao Z; Xing J; Chen B; Li J; Liu S
Cancer Lett; 2020 Jan; 469():89-101. PubMed ID: 31639424
[TBL] [Abstract][Full Text] [Related]
5. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.
Ahmed AA; Lu Z; Jennings NB; Etemadmoghadam D; Capalbo L; Jacamo RO; Barbosa-Morais N; Le XF; ; Vivas-Mejia P; Lopez-Berestein G; Grandjean G; Bartholomeusz G; Liao W; Andreeff M; Bowtell D; Glover DM; Sood AK; Bast RC
Cancer Cell; 2010 Aug; 18(2):109-21. PubMed ID: 20708153
[TBL] [Abstract][Full Text] [Related]
6. A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel.
Zhou J; Alfraidi A; Zhang S; Santiago-O'Farrill JM; Yerramreddy Reddy VK; Alsaadi A; Ahmed AA; Yang H; Liu J; Mao W; Wang Y; Takemori H; Vankayalapati H; Lu Z; Bast RC
Clin Cancer Res; 2017 Apr; 23(8):1945-1954. PubMed ID: 27678456
[No Abstract] [Full Text] [Related]
7. Inhibiting eukaryotic initiation factor 5A (eIF5A) hypusination attenuated activation of the SIK2 (salt-inducible kinase 2)-p4E-BP1 pathway involved in ovarian cancer cell proliferation and migration.
Lee GK; Kim HY; Park JH
Mol Biol Rep; 2023 Jul; 50(7):5807-5816. PubMed ID: 37219665
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor variant 12 promotes migration and invasion by regulating MYLK in gastric cancer.
Xia N; Cui J; Zhu M; Xing R; Lu Y
J Pathol; 2019 Jul; 248(3):304-315. PubMed ID: 30737779
[TBL] [Abstract][Full Text] [Related]
9. The AMPK-related kinase SIK2 is regulated by cAMP via phosphorylation at Ser358 in adipocytes.
Henriksson E; Jones HA; Patel K; Peggie M; Morrice N; Sakamoto K; Göransson O
Biochem J; 2012 Jun; 444(3):503-14. PubMed ID: 22462548
[TBL] [Abstract][Full Text] [Related]
10. SIK2 regulates CRTCs, HDAC4 and glucose uptake in adipocytes.
Henriksson E; Säll J; Gormand A; Wasserstrom S; Morrice NA; Fritzen AM; Foretz M; Campbell DG; Sakamoto K; Ekelund M; Degerman E; Stenkula KG; Göransson O
J Cell Sci; 2015 Feb; 128(3):472-86. PubMed ID: 25472719
[TBL] [Abstract][Full Text] [Related]
11. MYLK promotes hepatocellular carcinoma progression through regulating cytoskeleton to enhance epithelial-mesenchymal transition.
Lin J; He Y; Chen L; Chen X; Zang S; Lin W
Clin Exp Med; 2018 Nov; 18(4):523-533. PubMed ID: 29855744
[TBL] [Abstract][Full Text] [Related]
12. Involvement of SIK2/TORC2 signaling cascade in the regulation of insulin-induced PGC-1alpha and UCP-1 gene expression in brown adipocytes.
Muraoka M; Fukushima A; Viengchareun S; Lombès M; Kishi F; Miyauchi A; Kanematsu M; Doi J; Kajimura J; Nakai R; Uebi T; Okamoto M; Takemori H
Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1430-9. PubMed ID: 19351809
[TBL] [Abstract][Full Text] [Related]
13. Salt-Inducible Kinase 2-Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis.
Hua Y; Yin H; Liu X; Xie J; Zhan W; Liang G; Shen Y
Adv Sci (Weinh); 2022 Aug; 9(22):e2202260. PubMed ID: 35618488
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
15. SIK2: A critical glucolipid metabolic reprogramming regulator and potential target in ovarian cancer.
Hu D; Du J; Xing Y; Cheng Y; He R; Liang X; Li H; Yang Y
J Obstet Gynaecol Res; 2023 Aug; 49(8):2000-2009. PubMed ID: 37317594
[TBL] [Abstract][Full Text] [Related]
16. CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652.
Zhao Y; Hu Y; Shen Q; Chen Q; Zhu XJ; Jiang SS; Zhang Q
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5281-5291. PubMed ID: 32495861
[TBL] [Abstract][Full Text] [Related]
17. Salt-inducible kinase 2 and -3 are downregulated in adipose tissue from obese or insulin-resistant individuals: implications for insulin signalling and glucose uptake in human adipocytes.
Säll J; Pettersson AM; Björk C; Henriksson E; Wasserstrom S; Linder W; Zhou Y; Hansson O; Andersson DP; Ekelund M; Degerman E; Stenkula KG; Laurencikiene J; Göransson O
Diabetologia; 2017 Feb; 60(2):314-323. PubMed ID: 27807598
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells.
Sawada K; Morishige Ki; Tahara M; Ikebuchi Y; Kawagishi R; Tasaka K; Murata Y
Gynecol Oncol; 2002 Dec; 87(3):252-9. PubMed ID: 12468322
[TBL] [Abstract][Full Text] [Related]
19. Adipose-specific expression, phosphorylation of Ser794 in insulin receptor substrate-1, and activation in diabetic animals of salt-inducible kinase-2.
Horike N; Takemori H; Katoh Y; Doi J; Min L; Asano T; Sun XJ; Yamamoto H; Kasayama S; Muraoka M; Nonaka Y; Okamoto M
J Biol Chem; 2003 May; 278(20):18440-7. PubMed ID: 12624099
[TBL] [Abstract][Full Text] [Related]
20. MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data.
Tan X; Chen M
Tumour Biol; 2014 Dec; 35(12):12189-200. PubMed ID: 25179839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
